The preparation of platelet-rich plasma (PRP) requires precise density-based centrifugation of anticoagulated whole blood to achieve an optimal hematologic bioformulation while enhancing platelet recovery efficiency. Commercial PRP systems exhibit substantial heterogeneity in processing architecture, with variable platelet yields and inconsistent cellular composition profiles. In this clinical PRP device evaluation, 70 sequential samples sourced from two independent clinical facilities were used to evaluate the performance characteristics of the XCELL 60 mL single-spin centrifugation platform. Two different PRP preparations were consistently prepared as per physician preferences: PRP-1 and PRP-2. The main differences between these two preparations were the concentration of leukocytes and reduction in red blood cells. The system was evaluated based on critical PRP performance metrics. The results demonstrated the following: (1) A consistent 8-fold increase in platelet concentration relative to baseline whole blood was achieved. (2) The average platelet capture rate (PCR) was 83%. (3) The total available platelets (TAPs) in the PRP specimen produced from both groups combined were 10.8 ± 2595 billion platelets within a final product volume of 6 mL. (4) Hematocrit values were reduced to <2–6% across sites (reduction of 94% and 84% in RBCs, respectively). Finally, (5) a customizable leukocyte content (20.9–25.4 × 109/L) was achieved without comprising platelet yield. This single-spin centrifugation architecture achieved performance parity with historically preferred double-spin systems while reducing the processing time and number of preparation steps. Engineering analysis established that high-precision platelet recovery and bioformulation control are achievable through optimized single-spin centrifugal design, enabling standardized therapeutic dosing for autologous regenerative medicine applications.
Sussman et al. (Tue,) studied this question.